What are the indications for gabapentin (Neurontin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Gabapentin is primarily indicated for the treatment of partial seizures, postherpetic neuralgia, and neuropathic pain conditions, including diabetic peripheral neuropathy, with a recommended starting dose of 300 mg once daily, gradually increasing to 300-600 mg three times daily, with maximum doses ranging from 1800-3600 mg daily divided into three doses, as supported by the most recent and highest quality study 1.

Indications for Gabapentin

  • Partial seizures in adults and children over 3 years old, either as monotherapy or adjunctive therapy
  • Postherpetic neuralgia in adults
  • Neuropathic pain conditions, including:
    • Diabetic peripheral neuropathy
    • Fibromyalgia
    • Other types of nerve pain
  • Restless leg syndrome
  • Alcohol withdrawal
  • Hot flashes
  • Adjunct treatment for anxiety disorders

Dosage and Administration

  • Starting dose: 300 mg once daily
  • Gradually increase to 300-600 mg three times daily
  • Maximum doses: 1800-3600 mg daily divided into three doses
  • Dosage adjustments necessary in patients with renal impairment
  • Taper gradually when discontinuing to avoid withdrawal symptoms

Mechanism of Action

  • Binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system
  • Reduces the release of excitatory neurotransmitters
  • Effective in treating both seizures and neuropathic pain

Clinical Evidence

  • Supported by multiple studies, including 1, 1, 1, 1, 1, and 1
  • Recommended as an initial pharmacologic treatment for neuropathic pain in diabetes, along with pregabalin and duloxetine 1

From the FDA Drug Label

Gabapentin Tablets, USP are indicated for: Management of postherpetic neuralgia in adults Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy

The indications for gabapentin (Neurontin) are:

  • Management of postherpetic neuralgia in adults
  • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy 2

From the Research

Indications for Gabapentin

Gabapentin is indicated for various conditions, including:

  • Adjunctive treatment of complex partial seizures with and without generalization 3
  • Treatment of neuropathic pain, including painful diabetic neuropathy and postherpetic neuralgia 4, 5
  • Treatment of epilepsy, including partial seizures with or without secondary generalization 6, 7

Dosage and Administration

The dosage of gabapentin varies depending on the condition being treated and the patient's renal function.

  • For adjunctive treatment of complex partial seizures, the recommended dosage is 900-1800 mg/day 3
  • For treatment of neuropathic pain, the recommended dosage is 1800-3600 mg/day, with a starting dose of 900 mg/day 4, 5
  • For treatment of epilepsy, the recommended dosage is 900-3600 mg/day, with a starting dose of 900 mg/day 6, 7

Efficacy and Safety

Gabapentin has been shown to be effective in reducing pain and seizure frequency in various studies.

  • In patients with postherpetic neuralgia, gabapentin at doses of 1200 mg/day or greater was associated with substantial pain relief (at least 50% pain relief) in 32% of patients, compared to 17% with placebo 5
  • In patients with painful diabetic neuropathy, gabapentin at doses of 1200 mg/day or greater was associated with substantial pain relief in 38% of patients, compared to 21% with placebo 5
  • Gabapentin is generally well-tolerated, with common side effects including dizziness, somnolence, and peripheral edema 4, 5, 6, 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Gabapentin: a unique anti-epileptic agent.

Neurological research, 2001

Research

Gabapentin for chronic neuropathic pain in adults.

The Cochrane database of systematic reviews, 2017

Research

Gabapentin dosing in the treatment of epilepsy.

Clinical therapeutics, 2003

Research

Gabapentin.

Epilepsia, 1995

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.